Itruvone (PH10)
Major Depressive Disorder
Phase 2Active
Key Facts
About Vistagen Therapeutics
Vistagen Therapeutics is advancing a first-in-class pherine platform to develop fast-acting, non-addictive nasal sprays for major psychiatric disorders. Its lead candidate, fasedienol (PH94B), has demonstrated rapid-onset anxiolytic effects in Phase 3 trials for social anxiety disorder, positioning it as a potential breakthrough therapy. The company's strategy focuses on leveraging its novel, non-systemic mechanism to address high-unmet-need conditions while minimizing the drawbacks of conventional oral medications. Despite a challenging financial position and low market valuation, Vistagen's innovative approach represents a distinct and potentially disruptive opportunity in the neuropsychiatric space.
View full company profileTherapeutic Areas
Other Major Depressive Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| Accelerated Deep TMS Protocol | BrainsWay | FDA Cleared |
| ZURZUVAE (zuranolone) | Sage Therapeutics | Phase 3 |
| MDD Clinical Trials | Boston Clinical Trials | Not Specified (Typically Phase 2-3) |
| NMDAR Antagonist (GM-2505/Bretisilocin) | Gilgamesh Pharmaceuticals | Phase 2 |
| Neuroplastogen (GM-1020) | Gilgamesh Pharmaceuticals | Phase 2a |
| NA-901 | Biomed | Phase 2B/3 |
| SP-624 (Forvisirvat) | Arrivo BioVentures | Phase 2 |
| NBS System for MDD | Nexstim | Approved |
| Major Depressive Disorder Studies | Noesis Pharma Clinical Trials | Phase 2-4 |
| Depression Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| Neurotyping Platform for MDD | Universal Brain | Development |
| CLE-100 | Clexio Biosciences | Phase 2 |